false
0001763950
0001763950
2026-05-12
2026-05-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 12, 2026
Lantern
Pharma Inc.
(Exact
Name of Registrant as Specified in Its Charter)
| Delaware |
|
001-39318 |
|
46-3973463 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
Number) |
1920
McKinney Avenue, 7th Floor
Dallas, Texas 75201
(Address
of principal executive offices)
(972)
277-1136
(Registrant’s
telephone number, including area code)
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under
any of the following provisions.
| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b) |
| | |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b) |
| | |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c) |
Securities
registered pursuant to Section 12(b)of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common Stock, par value of $0.001 per share |
|
LTRN |
|
Nasdaq Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01 Entry into a Material Definitive Agreement.
On
May 12, 2026, Lantern Pharma Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”)
with institutional investors, pursuant to which the Company agreed to issue and sell to such investors in a registered direct offering
(i) 1,454,175 shares (the “Common Shares”) of common stock, par value $0.0001 per share (the “Common Stock”),
of the Company, at an offering price of $2.06 per share, and (ii) pre-funded warrants to purchase up to 681,748 shares of Common Stock
(the “Pre-Funded Warrants”) in lieu of the Common Shares, at an offering price of $2.0599 (such registered direct offering,
the “Offering”). The closing of the Offering occurred on May 14, 2026.
In
addition, in a concurrent private placement, the Company issued to such investors warrants to purchase up to 2,135,923 shares
of Common Stock (the “Purchase Warrants”), at an exercise price of $2.27 per share. The Purchase Warrants and the shares
of Common Stock issuable upon the exercise of such Purchase Warrants (the “Purchase Warrant Shares”) were
offered pursuant to the exemption provided in Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”)
and/or Rule 506(b) of Regulation D promulgated thereunder. A holder will not have the right to exercise any portion of the Purchase
Warrants if the holder (together with its affiliates) would beneficially own in excess of 4.99% (or, upon election of the holder, 9.99%)
of the number of shares of common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is
determined in accordance with the terms of the Purchase Warrants. However, any holder may increase or decrease such percentage, provided
that any increase will not be effective until the 61st day after such election. The Purchase Warrants are exercisable
six months following the initial issuance date and expire five years following the initial exercise date.
The
Company agreed to file a registration statement on Form S-1 with the Securities and Exchange Commission (the “SEC”) relating to the offer
and resale by the investors of the Purchase Warrant Shares within 30 days of the effective date of the Purchase Agreement and to use
commercially reasonable efforts to cause such registration statement to become effective within 60 days following the closing of the
offering (or 90 days in the event of a full SEC review).
Moreover,
the Purchase Agreement provides the investors with the right, subject to specified conditions, to participate on the same terms as other
investors in certain future equity financing of the Company’s contemplated subsidiary composed of the AI platform, withZeta.ai, and related
technologies, for a limited period following such subsidiary’s public emergence, up to an aggregate of 30% of such financing, excluding
certain exempt issuances. The Company has agreed to cause such subsidiary to assume these obligations and if such subsidiary is not timely
formed or does not complete its public emergence within the specified timeframes, similar participation rights will apply to certain
future equity financings of the Company.
In addition, the Purchase Agreement restricts the Company, for a period of two years following
the closing of the offering, from entering into or effecting any “Variable Rate Transaction,” which generally includes issuances of securities
where the conversion, exercise, or issuance price is variable, subject to future adjustment, or based on the trading price of the Company’s
common stock, as well as equity line or similar facilities permitting future issuances at indeterminate prices. The Purchase Agreement
provides that sales of the Company’s common stock under an at-the-market facility on or after the 75th day following the closing of the
offering does not constitute a Variable Rate Transaction.
Each
Pre-Funded Warrant entitles the holder to purchase one share (“Pre-Funded Warrant Share”) of Common Stock. The Pre-Funded
Warrants are immediately exercisable and may be exercised at a nominal consideration of $0.0001 per share of Common Stock at any time
until all of the Pre-Funded Warrants are exercised in full.
Pursuant
to an engagement letter dated April 20, 2026, Rodman and Renshaw, LLC (“Placement Agent”) acted as the sole placement
agent for the Offering. In consideration for the Placement Agent serving as the placement agent for the Offering, the Company paid
the Placement Agent a cash fee equal to 7% of the aggregate gross proceeds of the Offering and reimbursed the Placement Agent
for certain expenses and legal fees. In addition, the Company issued to the Placement Agent or its designees warrants to purchase
5% of the Common Shares (or Pre-Funded Warrants in lieu thereof) sold in the Offering (the “Placement Agent Warrants”). The
Placement Agent Warrants have substantially the same terms as the Purchase Warrants except that the Placement Agent Warrants have an exercise price of $2.575 (125% of Common Share purchase price) and will expire on the fifth anniversary of the commencement of
sales in the Offering. The Company has also agreed to pay the Placement Agent a cash fee of 3.0% of the gross exercise price paid in
cash with respect to the exercise of any Purchase Warrants issued in the concurrent private placement.
The
Common Shares, the Pre-Funded Warrants and Pre-Funded Warrant Shares were offered pursuant to a “shelf” registration
statement on Form S-3 (File No. 333-279718) that was declared effective by the SEC on June 10, 2024, and a prospectus supplement
that was filed with the SEC on May 14, 2026 in connection with the Offering.
The
Company received gross proceeds of approximately $4.4 million from the Offering, before deducting Offering expenses
payable by the Company, including the Placement Agent’s fees. The Company intends to use the net proceeds from the Offering for
working capital and general corporate purposes.
The
Securities Purchase Agreement, form of the Pre-Funded Warrant, form of the Purchase Warrant and form of the Placement Agent Warrant are
filed as exhibits to this Current Report on Form 8-K (this “Form 8-K”) and are incorporated by reference herein.
The
Company issued press releases announcing the pricing and closing of the Offering on May 13, 2026 and May 14,
2026, respectively. Copies of these press releases are attached hereto as Exhibits 99.1 and 99.2, respectively,
and are incorporated herein by reference.
A
copy of the legal opinion and consent of Greenberg Traurig, LLP relating to the Common Shares, Pre-Funded Warrants and Pre-Funded Warrant
Shares is attached hereto as Exhibit 5.1.
Item
3.02 Unregistered Sale of Equity Securities.
The
applicable information set forth in Item 1.01 of this Form 8-K with respect to the Purchase Warrants, and the Placement Agent Warrants,
and the underlying shares of Common Stock issuable thereunder is incorporated herein by reference.
Item
8.01 Other Events.
On
May 13, 2026, the Company announced, by way of the press release attached hereto as Exhibit 99.1, the pricing of the offering described
above and plans to create an independent business entity composed of the AI platform, withZeta.ai, and related technologies and personnel
under the leadership of CEO Mr. Panna Sharma. The Company intends to separate its public facing AI technology assets into an independent
business entity in order to access dedicated funding sources and potentially realize valuation multiples separate from its primary drug
development operations, which such entity may potentially become a newly listed company on a national stock exchange or market. The Company
plans on hosting a separate investor webinar and meeting to provide additional details in the coming month.
On
May 12, 2026, the Company suspended offers and sales of the shares of Common Stock pursuant to the prospectus supplement, dated July
3, 2025, relating to the ATM Sales Agreement, dated July 3, 2025 (the “Sales Agreement”), by and between the Company and
ThinkEquity LLC. The Company will not make any sales of shares of Common Stock pursuant to the Sales Agreement unless and until a new
prospectus supplement is filed with the SEC; however, the Sales Agreement remains in full force and effect.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits
The
following exhibits are filed with this report:
Exhibit
Number |
|
Exhibit
Description |
| 4.1 |
|
Form of Pre-Funded Common Stock Purchase Warrant |
| 4.2 |
|
Form of Purchase Warrant |
| 4.3 |
|
Form of Placement Agent Warrant |
| 5.1 |
|
Legal Opinion of Greenberg Traurig, LLP |
| 10.1 |
|
Securities Purchase Agreement |
| 23.1 |
|
Consent of Greenberg Traurig, LLP (included in Exhibit 5.1) |
| 99.1 |
|
Press release dated May 13, 2026 announcing the pricing of the Offering |
| 99.2 |
|
Press release dated May 14, 2026 announcing the closing of the Offering |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
Lantern Pharma Inc. |
| |
|
|
| Dated:
May 14, 2026 |
By: |
/s/
David Margrave |
| |
|
David
Margrave |
| |
|
Chief
Financial Officer |
Exhibit
99.1
Lantern
Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
$4.4
million upfront with up to an additional $4.85 million of potential aggregate gross proceeds upon the exercise in full of the warrants
Offering
priced at the closing price with unregistered warrants exercisable at a 10% premium to the close and non-exercisable for the first six
months
DALLAS—(BUSINESS
WIRE)—Lantern Pharma Inc. (NASDAQ: LTRN) (“Lantern” or the “Company”), a clinical-stage AI-driven precision
oncology company developing targeted and transformative cancer therapies using its proprietary AI and machine learning platforms with
multiple clinical stage drug programs, today announced that it has entered into a definitive agreement for the purchase and sale of an
aggregate of 2,135,923 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $2.06 per share (or
pre-funded warrant in lieu thereof) in a registered direct offering. In addition, in a concurrent private placement, the Company will
issue unregistered warrants to purchase up to 2,135,923 shares of common stock. The warrants will have an exercise price of $2.27 per
share, will be exercisable six months following the initial issuance date, and will expire five years following the initial exercise
date. The closing of the offering is expected to occur on or about May 14, 2026, subject to the satisfaction of customary closing conditions.
The
Company has also communicated plans to create an independent business entity composed of the AI platform, withZeta.ai, and
related technologies and personnel under the leadership of CEO Mr. Panna Sharma. The Company intends to separate its public facing clinically
trained AI agent into an independent business entity in order to access dedicated funding sources and potentially realize valuation multiples
separate from its drug development operations, which such entity the Company anticipates will become a newly listed company on a national
stock exchange or market. Ryan Lane, from Empery Asset Management, whose funds led the financing round, commented: “We started
using the AI platform shortly after its public release and have found the prompt results exceptionally useful for our in-house compound
viability analysis versus generic LLM models. We believe with additional funding, withZeta will become a leading AI co-scientist for
investors and biotech executives.”
The Company
plans on hosting a separate investor webinar and meeting to provide additional details in the coming month.
Rodman
& Renshaw LLC is acting as the exclusive placement agent for the offering.
The
aggregate gross proceeds to the Company from the offering are expected to be approximately $4.4 million, before deducting the placement
agent fees and other offering expenses payable by the Company. The potential additional gross proceeds from the unregistered warrants,
if fully exercised on a cash basis, will be approximately $4.85 million. No assurance can be given that any of the warrants will be exercised.
The Company currently intends to use the net proceeds from the offering for working capital and other general corporate purposes.
The
shares of common stock (or pre-funded warrants in lieu thereof) (but not the warrants issued in the private placement or the shares of
common stock underlying such warrants) are being offered by the Company pursuant to a “shelf” registration statement on Form
S-3 (File No. 333-279718) filed with the Securities and Exchange Commission (“SEC”) on May 24, 2024, and became effective
on June 10, 2024. The registered direct offering of the shares of common stock (or pre-funded warrants in lieu thereof) is being made
only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. The prospectus
supplement and the accompanying prospectus relating to the shares of common stock (or pre-funded warrants in lieu thereof) being offered
in the registered direct offering will be filed with the SEC and be available at the SEC’s website at www.sec.gov. Electronic copies
of the prospectus supplement and the accompanying prospectus relating to the registered direct offering may also be obtained, when available,
by contacting Rodman & Renshaw LLC at 600 Lexington Avenue, 32nd Floor, New York, NY 10022, by telephone at (212) 540-4414, or by
email at info@rodm.com.
The
warrants described above are being issued in a concurrent private placement under Section 4(a)(2) of the Securities Act of 1933, as amended
(the “Securities Act”), and Regulation D promulgated thereunder and, along with the shares of common stock underlying the
warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the warrants and underlying
shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable
exemption from the registration requirements of the Securities Act and such applicable state securities laws.
This
press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor
shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful
prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About
Lantern Pharma
Lantern
Pharma (NASDAQ: LTRN) is a clinical-stage AI-driven precision oncology company transforming the cost, pace, and timeline of oncology
drug discovery and development. The company’s proprietary AI and machine learning platform, RADR®, now operationalized through
withZeta.ai, leverages billions of data points and advanced computational methods to rapidly uncover biomarker signatures and accelerate
the development of targeted oncology therapies for difficult-to-treat cancers, including those of the central nervous system. Lantern
is currently advancing a pipeline of small molecule drug candidates and an antibody-drug conjugate program focused on multiple solid
tumor and hematologic malignancies. For more information, visit:
Website:
www.lanternpharma.com
LinkedIn:
https://www.linkedin.com/company/lanternpharma/
X:
@lanternpharma
Forward-Looking
Statements
This
press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating
to the ability of the Company to consummate the offering, the satisfaction of the closing conditions of the offering, the intended use
of proceeds from the offering, the exercise of the warrants prior to their expiration, and the listing of an independent business entity
of the Company on a on a national stock exchange or market.
Any
statements that are not statements of historical fact (including, without limitation, statements that use words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “model,” “objective,” “aim,” “upcoming,” “should,”
“will,” “would,” or the negative of these words or other similar expressions) should be considered forward-looking
statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by
the forward-looking statements, such as (i) the risk that the Company may not be able to secure sufficient future funding when needed
and as required to advance and support our existing and planned development programs and operations, (ii) the risk that observations
in preclinical studies and early or preliminary observations in clinical studies do not ensure that later observations, studies and development
will be consistent or successful, (iii) the risk that our research and the research of our collaborators may not be successful, (iv)
the risk that our AI platform commercialization efforts, including withZeta.ai, may not generate the anticipated revenue or achieve the
expected market adoption, (v) the risk that none of our product candidates has received FDA marketing approval, and we may not be able
to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (vi) the
risk that no drug product based on our proprietary AI platforms has received FDA marketing approval or otherwise been incorporated into
a commercial product, (vii) market and other conditions, and (viii) those other factors set forth in the Risk Factors section in our
Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 30, 2026.
You
may access our Annual Report on Form 10-K for the year ended December 31, 2025 under the investor SEC filings tab of our website at http://www.lanternpharma.com/
or on the SEC’s website at http://www.sec.gov/. Given these risks and uncertainties, the Company can give no assurances that our
forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking
statements will in fact occur, and the Company cautions investors not to place undue reliance on these statements. All forward-looking
statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, the Company
disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.
Contacts
Investor
Contact
Investor Relations
ir@lanternpharma.com
+1-972-277-1136
Exhibit
99.2
Lantern
Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
$4.4
million upfront with up to an additional $4.85 million of potential aggregate gross proceeds upon the exercise in full of the warrants
Offering
priced at the closing price with unregistered warrants exercisable at a 10% premium to the close and non-exercisable for the first six
months
DALLAS,
TEXAS — (BUSINESS WIRE) — May 14, 2026 – Lantern Pharma Inc. (NASDAQ: LTRN) (“Lantern” or the “Company”),
a clinical-stage AI-driven precision oncology company developing targeted and transformative cancer therapies using its proprietary AI
and machine learning platforms with multiple clinical stage drug programs, today announced the closing of its previously announced registered
direct offering of 2,135,923 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $2.06 per share
(or pre-funded warrant in lieu thereof). In addition, in a concurrent private placement, the Company issued unregistered warrants to
purchase up to 2,135,923 shares of common stock. The warrants have an exercise price of $2.27 per share, are exercisable six months following
the initial issuance date, and will expire five years following the initial exercise date.
Rodman
& Renshaw LLC acted as the exclusive placement agent for the offering.
The
aggregate gross proceeds to the Company from the offering were approximately $4.4 million, before deducting the placement agent fees
and other offering expenses payable by the Company. The potential additional gross proceeds from the unregistered warrants, if fully
exercised on a cash basis, will be approximately $4.85 million. No assurance can be given that any of the warrants will be exercised.
The Company currently intends to use the net proceeds from the offering for working capital and other general corporate purposes.
The
shares of common stock (or pre-funded warrants in lieu thereof) (but not the warrants issued in the private placement or the shares of
common stock underlying such warrants) were offered by the Company pursuant to a “shelf” registration statement on Form S-3
(File No. 333-279718) filed with the Securities and Exchange Commission (“SEC”) on May 24, 2024, and became effective on
June 10, 2024. The registered direct offering of the shares of common stock (or pre-funded warrants in lieu thereof) was made only by
means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. The prospectus supplement
and the accompanying prospectus relating to the shares of common stock (or pre-funded warrants in lieu thereof) offered in the registered
direct offering were filed with the SEC and are available at the SEC’s website at www.sec.gov. Electronic copies of the prospectus
supplement and the accompanying prospectus relating to the registered direct offering may also be obtained by contacting Rodman &
Renshaw LLC at 600 Lexington Avenue, 32nd Floor, New York, NY 10022, by telephone at (212) 540-4414, or by email at info@rodm.com.
The
warrants described above were issued in a concurrent private placement under Section 4(a)(2) of the Securities Act of 1933, as amended
(the “Securities Act”), and Regulation D promulgated thereunder and, along with the shares of common stock underlying the
warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the warrants and underlying
shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable
exemption from the registration requirements of the Securities Act and such applicable state securities laws.
This
press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor
shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful
prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About
Lantern Pharma
Lantern
Pharma (NASDAQ: LTRN) is a clinical-stage AI-driven precision oncology company transforming the cost, pace, and timeline of oncology
drug discovery and development. The company’s proprietary AI and machine learning platform, RADR®, now operationalized through
withZeta.ai, leverages billions of data points and advanced computational methods to rapidly uncover biomarker signatures and accelerate
the development of targeted oncology therapies for difficult-to-treat cancers, including those of the central nervous system. Lantern
is currently advancing a pipeline of small molecule drug candidates and an antibody-drug conjugate program focused on multiple solid
tumor and hematologic malignancies. For more information, visit:
www.lanternpharma.com
LinkedIn:
https://www.linkedin.com/company/lanternpharma/
X: @lanternpharma
Forward-Looking
Statements
This
press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating
to the use of proceeds from the offering and the exercise of the warrants prior to their expiration.
Any
statements that are not statements of historical fact (including, without limitation, statements that use words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “model,” “objective,” “aim,” “upcoming,” “should,”
“will,” “would,” or the negative of these words or other similar expressions) should be considered forward-looking
statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by
the forward-looking statements, such as (i) the risk that the Company may not be able to secure sufficient future funding when needed
and as required to advance and support our existing and planned development programs and operations, (ii) the risk that observations
in preclinical studies and early or preliminary observations in clinical studies do not ensure that later observations, studies and development
will be consistent or successful, (iii) the risk that our research and the research of our collaborators may not be successful, (iv)
the risk that our AI platform commercialization efforts, including withZeta.ai, may not generate the anticipated revenue or achieve the
expected market adoption, (v) the risk that none of our product candidates has received FDA marketing approval, and we may not be able
to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (vi) the
risk that no drug product based on our proprietary AI platforms has received FDA marketing approval or otherwise been incorporated into
a commercial product, (vii) market and other conditions, and (viii) those other factors set forth in the Risk Factors section in our
Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 30, 2026.
You
may access our Annual Report on Form 10-K for the year ended December 31, 2025 under the investor SEC filings tab of our website at http://www.lanternpharma.com/
or on the SEC’s website at http://www.sec.gov/. Given these risks and uncertainties, the Company can give no assurances that our
forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking
statements will in fact occur, and the Company cautions investors not to place undue reliance on these statements. All forward-looking
statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, the Company
disclaims any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.
Investor
Contact
Investor Relations
ir@lanternpharma.com
+1-972-277-1136
